Key Points CMS finalized nationally published physician valuations for skin cell suspension autograft procedures performed using RECELL, effective January

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

- There is an urgent need for interventions that improve healing time, prevent amputations and recurrent ulceration in patients with diabetes-related foot wounds. In this randomised, open-label trial, participants were randomised to receive an application of non-cultured autologous skin cells ("spray- … — Read on pubmed.ncbi.nlm.nih.gov/34156758/ There was no difference in healing between active and control There is an urgent need for interventions that improve healing time, prevent amputations and recurrent ulceration in patients with diabetes-related foot wounds. In this randomised, open-label trial, participants were randomised to receive an application of non-cultured autologous skin cells ("spray- … — Read on pubmed.ncbi.nlm.nih.gov/34156758/ There was no difference in healing between active and control There is an urgent need for interventions that improve healing time, prevent amputations and recurrent ulceration in patients with diabetes-related foot wounds. In this randomised, open-label trial, participants were randomised to receive an application of non-cultured autologous skin cells ("spray- … — Read on pubmed.ncbi.nlm.nih.gov/34156758/ There was no difference in healing between active and control - -

A pulse-test diagnostic node that estimates second-life EV battery health in minutes using edge AI on Arduino UNO Q - no expensive lab equip

Cellular grafting with ReCell results in superior repigmentation compared with standard tissue grafting in select populations with stable vitiligo.

The company has created a board that can overrule even Mark Zuckerberg. Soon it will decide whether to allow Trump back on Facebook.

自宅で手軽にケアできる「ファイン オートファジー ReCell」が、TV番組で紹介され、「ベストハッピーアワード2025」を受賞。新しい美容健康の形をご紹介します。

Background: Skin grafting is currently the gold standard for managing traumatic skin defects. However, split thickness skin grafting, the most common technique, is challenging as it yields a limited amount of skin and creates a new wound at the healthy donor site. RECELL® (Avita Medical, Cambridge, UK), a non-cultured skin cell suspension technique, yields results with comparable duration and healing quality to skin grafting for burn trauma. Although RECELL® is widely used for burn trauma, its use for severe traumatic skin defects is not yet prevalent in Japan. Objective: To evaluate the utility of the RECELL® skin reconstruction technique in trauma cases involving significant skin defects. Specifically, the primary aim was to validate the efficacy of the RECELL® skin reconstruction technique when combined with split-thickness mesh grafting in patients with significant post-traumatic skin defects, particularly focusing on wound closure and scar quality. Methods: This prospective, single-center, open-label pilot #Study will enroll patients aged ≥16 years with traumatic limb skin defects ≥160 cm² and sufficient dermal-like tissue. Participants will undergo RECELL®-assisted autologous skin grafting with mesh grafts under general anesthesia. Wound healing, scarring (Vancouver Scar Scale), and pain (Visual Analog Scale) will be assessed up to 24 weeks postoperatively. The primary endpoint is ≥95% re-epithelialization at postoperative day 14. Descriptive statistical analyses will be performed to evaluate outcomes and inform future randomized trials. Results: Ethical approval has been obtained from the Nara Medical University Certified Review Board (CRB5200002), and the trial was registered under the number jRCTs052230203. Patient recruitment began in April 2024 and is currently ongoing in our hospital. As of April 10, 2025, ten patients have been screened, of whom four were enrolled. No adverse events or #Protocol deviations were noted. Conclusions: Overall, the #Study for which this #Protocol was written aims to validate the utility of RECELL® for skin defects resulting from trauma by assessing wound closure and scar formation, including adverse events, delayed healing, infection, and durability. Clinical Trial: Nara Medical University Certified Review Board 89 (CRB5200002) Japan Registry of Clinical Trials (jRCTs052230203).

BATON ROUGE - Burns are among the most painful injuries a person can endure. However, a relatively new treatment called ReCell ‘Spray-On Skin’ is changing the healing process for patients across Louisiana, offering quicker recovery, less pain, and dramatically improved cosmetic results.

Dr. Victoria Miles discusses how RECELL, which creates an autologous skin cell suspension, is reshaping burn care, access, and outcomes.

American Battery Technology Company (NASDAQ:ABAT) is among the 7 Best Manganese Stocks to Buy Right Now. American Battery Technology Company (NASDAQ:ABAT) has received a $1 million partnership agreeme...

Recell Exchange helps you trade in or sell old smartphones and electronics. Learn how to use the service to get the best value for your used devices.

Reported Thursday, Jun 18 - 8:49am EDT (TheFly subscription required to read more.)

Reported Wednesday, Apr 29 - 5:01pm EDT (TheFly subscription required to read more.)